A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities.Attitudes towards cytology and human papillomavirus self-sample collection for cervical screening among Hindu women in London, UK: a mixed methods study.Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions.Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical settingRisk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.The combined contraceptive pill.Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.Barriers to cervical screening in women who have experienced sexual abuse: an exploratory study.Hormonal contraception: recent advances.Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyImproving the quality of communication in organised cervical cancer screening programmes.Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears.HPV vaccine: Cervarix.Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December 2009.Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.New technologies and procedures for cervical cancer screening.Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis.Women's attitudes towards monthly bleeding: results of a global population-based survey.Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact.A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening.Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.50 years of "The Pill": celebrating a golden anniversary.Double blind peer review: Response rate was only 7.7%.Another flawed database study.Exploring the acceptability of two self-sampling devices for human papillomavirus testing in the cervical screening context: a qualitative study of Muslim women in London.Depo Provera and bone density.HPV vaccines: peering through the fog.Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.Randomized trial of the effect of tailored versus standard use of the combined oral contraceptive pill is not the second largest RCT.Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males.Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears.Sisters doing it for themselves.Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.
P50
Q30276176-EE4FD10E-828A-4882-8C68-9BAB634EC267Q30456505-C7C58380-8BE3-497F-8E1B-6CD7466A35B0Q30658918-07AAB1C5-A795-4DCE-81F5-B789AE23D01DQ33574454-34644357-DAD9-434A-81D2-644C12B66677Q33943610-5F04416D-8D07-4E1F-9A92-4D6F072FB097Q33953881-AE0C040B-A2A0-48C9-8F8C-C4828E2B835DQ34610151-3C84209A-2A37-4633-BFEB-E92DE87659B3Q35048280-05051E2B-43F1-4FB8-A5B5-E4236A28587EQ35160800-58C0CC85-870A-4B23-BD35-AC14C09C0B7AQ35221177-9557E16B-294B-413C-BA9F-AA9145BCDEA0Q36314645-F66FC640-20A3-464A-8DC3-86AA4D52FD33Q36484806-5C7696D9-3D27-4E68-A3CC-1BB55F5CCBEAQ37135912-A3B2191F-4D6C-4FDB-9FA7-B76EBBE5103BQ37185864-195EB4A3-B70E-49C2-A2F8-3B97D7561EEEQ37310663-77B4A21E-D88D-45E0-803C-EF41D2A652E8Q37687426-E8FDC228-C400-44D1-8EA4-AC7897A97832Q37775717-79C3FBE3-D284-4F2F-B3A3-8DD080A1C201Q37848169-1FBD15CD-78C5-4A76-9DAF-77AFB5EB2E7DQ38064058-90AF957A-CB62-4A18-A77C-3435C2FEB1A2Q38123772-6F48B9B2-1CC5-4741-B8B5-2DA089A37CD8Q39008052-E4F387F2-BD6F-4502-B125-8566DF8CFAFCQ39592363-C6166B5A-62B6-4242-9AFD-690236ECB04DQ40452486-451384FF-A5A6-40E1-B04A-CB1CDEC6CAE1Q41658208-947327ED-A462-4BBD-851C-3B502282714BQ41753328-E04D8584-D8CB-443B-AB5A-056FEF16BD3DQ42822639-6369525A-D921-488C-9AF4-64131C619757Q43046234-16717B2A-97F0-46CE-9CD4-924B597B2B1BQ43686885-0864F18A-FA67-4F7B-9CFF-9A99EA31E91FQ43991363-86947941-0647-4C68-8F8D-02D9318A5FE2Q44209850-5474173D-B14A-4D93-BB8C-594E4EF5673DQ44242302-28589CBD-F15B-4BD6-99E8-A20CEA598076Q44350321-AB07B32E-D422-4BB3-A57B-655818BC61CDQ45160629-2DD90123-ADF3-4AAE-85FB-C619899E0AA4Q46901387-34B5A26E-26EC-4B2E-AE65-26849855D814Q47291087-1EE688AA-8451-4046-9DE0-2DA95EE23AF4Q49169372-0FACC73F-67C4-41B0-B4E8-B45641D6F006Q51426652-CB165FA8-5713-4E45-9345-54C4972762E6Q51693574-F5B1E5B1-BE14-4905-A9CF-AF7EA819C973Q51841027-3D072864-893C-454C-AE35-BA469DE6FB88Q51895139-62C58FE9-3229-4DB1-A420-251D027D2920
P50
description
epidemiologist
@en
name
Anne Szarewski
@ast
Anne Szarewski
@en
Anne Szarewski
@es
Anne Szarewski
@nl
type
label
Anne Szarewski
@ast
Anne Szarewski
@en
Anne Szarewski
@es
Anne Szarewski
@nl
prefLabel
Anne Szarewski
@ast
Anne Szarewski
@en
Anne Szarewski
@es
Anne Szarewski
@nl
P1015
P214
P244
P269
P1005
P1015
P106
P1207
P1315
P1695
P19
P21
P213
0000 0001 1757 8552
P214
P244
P269
P271
DA13866631